Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
65.879,57
-1,31%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Capricor Therapeutics Inc (CAPR) Capricor Therapeutics Inc (CAPR) Notizie

CAPR

Capricor Therapeutics (CAPR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CAPR
DataOraFonteTitoloSimboloCompagnia
14/06/202422:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
11/06/202415:25GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayNASDAQ:CAPRCapricor Therapeutics Inc
04/06/202415:00GlobeNewswire Inc.Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
15/05/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
14/05/202415:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
13/05/202422:05GlobeNewswire Inc.Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
09/05/202415:15GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
08/05/202415:00GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
06/05/202415:00GlobeNewswire Inc.Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13NASDAQ:CAPRCapricor Therapeutics Inc
24/04/202415:00GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
21/03/202413:30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
11/03/202413:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CAPRCapricor Therapeutics Inc
29/02/202422:05GlobeNewswire Inc.Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
27/02/202414:30GlobeNewswire Inc.Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
22/02/202414:30GlobeNewswire Inc.Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29NASDAQ:CAPRCapricor Therapeutics Inc
20/02/202414:30GlobeNewswire Inc.Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward CommercializationNASDAQ:CAPRCapricor Therapeutics Inc
16/02/202423:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CAPRCapricor Therapeutics Inc
24/01/202415:15GlobeNewswire Inc.Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2NASDAQ:CAPRCapricor Therapeutics Inc
04/01/202423:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
17/10/202322:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323:00Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:CAPRCapricor Therapeutics Inc
07/09/202300:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
15/06/202323:27Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CAPRCapricor Therapeutics Inc
13/06/202323:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CAPRCapricor Therapeutics Inc
17/05/202301:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CAPRCapricor Therapeutics Inc
12/05/202315:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CAPRCapricor Therapeutics Inc
17/04/202323:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CAPRCapricor Therapeutics Inc
17/03/202322:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CAPRCapricor Therapeutics Inc
31/01/202312:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CAPRCapricor Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CAPR

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network